Login / Signup

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.

Kim R M BlenmanMichał MarczykThomas KarnTao QingXiaotong LiVignesh GunasekharanVesal YaghoobiYalai BaiEiman Y IbrahimTristen ParkAndrea L M SilberDenise M WolfEmily ReisenbichlerCarsten DenkertBruno Valentin SinnMariya RozenblitJulia FoldiDavid L RimmSibylle LoiblLajos Pusztai
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The TGFβ pathway is associated with immune-poor phenotype and RD in bTNBC. Among immune-rich bTNBC RD, macrophage/neutrophil chemoattractants dominate the cytokine milieu, and IFNγ and activated B cells and T cells dominate immune-rich cancers with pCR.
Keyphrases
  • low dose
  • rectal cancer
  • immune response
  • adipose tissue
  • squamous cell carcinoma
  • transforming growth factor
  • cancer therapy
  • young adults
  • signaling pathway
  • epidermal growth factor receptor